semaglutide fda lawsuit 🚨 A major just escalated pressure on compounded GLP-1s in Med Spas Last week, Novo Nordisk filed suit against telehealth company Hims & Hers over compounded products, signaling intensifying legal Compound versions of GLP-1 drugs

And symptoms can persist for years after as well, into menopause

In 2023, Juan P Frias and colleagues, in The Lancet, published the first phase two clinical trial of orforglipron, which investigated the use of a small-molecule oral GLP-1R agonist called orforglipron in type 2 diabetes, which can be taken at any time of the day without restrictions on food and water intake (Frias et al., 2023)

Avoid high-fat, greasy, or heavily spiced meals

Without research that directly examines these risks in RA patients, some doctors may feel that the potential downsides outweigh the possible benefits

drug supply.

Semaglutide research is ongoing, truly exciting, and developing in unexpected new directions